Literature DB >> 1542323

An economic evaluation of asthma in the United States.

K B Weiss1, P J Gergen, T A Hodgson.   

Abstract

BACKGROUND: Asthma is a common chronic illness. Recently, increases in morbidity and mortality due to this disease have been reported. We studied the distribution of health care resources used for asthma in order to lay the groundwork for further policy decisions aimed at reducing the economic burden of this disorder.
METHODS: Estimates of direct medical expenditures and indirect costs (in 1985 dollars) were derived from data available from the National Center for Health Statistics. These cost estimates were projected to 1990 dollars.
RESULTS: The cost of illness related to asthma in 1990 was estimated to be $6.2 billion. Inpatient hospital services represented the largest single direct medical expenditure for this chronic condition, approaching $1.6 billion. The value of reduced productivity due to loss of school days represented the largest single indirect cost, approaching $1 billion in 1990. Although asthma is often considered to be a mild chronic illness treatable with ambulatory care, we found that 43 percent of its economic impact was associated with emergency room use, hospitalization, and death. Nearly two thirds of the visits for ambulatory care were to physicians in three primary care specialties--pediatrics, family medicine or general practice, and internal medicine.
CONCLUSIONS: Potential reductions in the costs related to asthma in the United States may be identified through a closer examination of the effectiveness of care associated with each category of cost. Future health policy efforts to improve the effectiveness of primary care interventions for asthma in the ambulatory setting may reduce the costs of this common illness.

Entities:  

Mesh:

Year:  1992        PMID: 1542323     DOI: 10.1056/NEJM199203263261304

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  110 in total

1.  Asthma outcome measures.

Authors:  K D Watkins
Journal:  J Med Syst       Date:  1999-08       Impact factor: 4.460

2.  First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma.

Authors:  L Blais; S Suissa; J F Boivin; P Ernst
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 3.  Pharmacologic management of the hospitalized pediatric asthma patient.

Authors:  K A Hardin; H J Kallas; R J McDonald
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

Review 4.  Complex interactions in complex traits: obesity and asthma.

Authors:  K G Tantisira; S T Weiss
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

5.  Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid population.

Authors:  L T Piecoro; M Potoski; J C Talbert; D E Doherty
Journal:  Health Serv Res       Date:  2001-06       Impact factor: 3.402

Review 6.  Chronic bronchial asthma from challenge to treatment: epidemiology and social impact.

Authors:  M Neri; A Spanevello
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

7.  The influence of chronic respiratory conditions on health status and work disability.

Authors:  Mark D Eisner; Edward H Yelin; Laura Trupin; Paul D Blanc
Journal:  Am J Public Health       Date:  2002-09       Impact factor: 9.308

Review 8.  Recent advances in asthma.

Authors:  P J Barnes; T H Lee
Journal:  Postgrad Med J       Date:  1992-12       Impact factor: 2.401

9.  Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma.

Authors:  S Suissa; P Ernst; A Kezouh
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

10.  Longitudinal validation of a tool for asthma self-monitoring.

Authors:  Flory L Nkoy; Bryan L Stone; Bernhard A Fassl; Derek A Uchida; Karmella Koopmeiners; Sarah Halbern; Eun H Kim; Allison Wilcox; Jian Ying; Tom H Greene; David M Mosen; Michael N Schatz; Christopher G Maloney
Journal:  Pediatrics       Date:  2013-11-11       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.